Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Antidepressant Drug Design on TCAs and Phenoxyphenylpropylamines Utilizing QSAR and Pharmacophore Modeling

Author(s): Amit Kumar, Sisir Nandi* and Anil Kumar Saxena*

Volume 25, Issue 3, 2022

Published on: 01 September, 2020

Page: [451 - 461] Pages: 11

DOI: 10.2174/1386207323666200901104222

Price: $65

Abstract

Background: Depression is a mental illness caused by the imbalance of important neurotransmitters such as serotonin (5-HT) and norepinephrine (NE). It is a serious neurological disorder that could be treated by antidepressant drugs.

Objective: There are two major classes, such as TCAs and phenoxyphenylpropylamines, which have been proven to be broad-spectrum antidepressant compounds. Several attempts were made to design, synthesize and discover potent antidepressant compounds having the least toxicity and most selectivity towards serotonin and norepinephrine transporters. However, there is hardly any drug design based on quantitative structure-activity relationship (QSAR) and pharmacophore modeling attempted yet.

Method: In the present study, many TCAs (dibenzoazepine) and phenoxyphenylpropylamine derivatives are taken into consideration for pharmacophore feature generation followed by pharmacophoric distant related descriptors based QSAR modeling. Furthermore, several five new congeners have been designed which are subjected to the prediction of biological activities in terms of serotonin receptor affinity utilizing validated QSAR models developed by us.

Results: An important pharmacophoric feature point C, followed by the generation of a topography of the TCAs and phenoxyphenylpropylamine, has been predicted. The developed pharmacophoric feature-based QSAR can explain 64.2% of the variances of 5-HT receptor antagonism. The best training model has been statistically validated by the prediction of test set compounds. This training model has been used for the prediction of some newly designed congeneric compounds which are comparable with the existed drugs.

Conclusion: The newly designed compounds may be proposed for further synthesis and biological screening as antidepressant agents.

Keywords: TCAs (dibenzoazepine), phenoxyphenylpropylamine, pharmacophore, QSAR, pharmacophoric distance-based topograph, antidepressant drug design

« Previous Next »
Graphical Abstract

[1]
Lemke, T.L.; Williams, D.A.; Roche, V.F.; Zito, S.W. Foye’s Principles of Medicinal Chemistry, 6th ed; Lippincott Williams & Wilkins: Philadelphia, 2010.
[2]
National Institute of Mental Health. Depression Publication no. 00-3561, 2000.
[3]
National Institutes of Mental Health. Real men; real depression. Publication no. 03-4972, 2003.
[4]
Coppen, A.; Prange, A.J., Jr; Whybrow, P.C.; Noguera, R. Abnormalities of indoleamines in affective disorders. Arch. Gen. Psychiatry, 1972, 26(5), 474-478.
[http://dx.doi.org/10.1001/archpsyc.1972.01750230084016] [PMID: 5019886]
[5]
Labrid, C.; Moleyre, J.; Poignant, J.C.; Malen, C.; Mocaër, E.; Kamoun, A. Structure-activity relationships of tricyclic antidepressants, with special reference to tianeptine. Clin. Neuropharmacol., 1988, 11(Suppl. 2), S21-S31.
[PMID: 3180115]
[6]
Casarotto, M.G.; Craik, D.J. Ring flexibility within tricyclic antidepressant drugs. J. Pharm. Sci., 2001, 90(6), 713-721.
[http://dx.doi.org/10.1002/jps.1027] [PMID: 11357174]
[7]
Gillman, P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol., 2007, 151(6), 737-748.
[http://dx.doi.org/10.1038/sj.bjp.0707253] [PMID: 17471183]
[8]
Hyttel, J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol., 1994, 9(Suppl. 1), 19-26.
[http://dx.doi.org/10.1097/00004850-199403001-00004] [PMID: 8021435]
[9]
Sánchez, C.; Hyttel, J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol., 1999, 19(4), 467-489.
[http://dx.doi.org/10.1023/A:1006986824213] [PMID: 10379421]
[10]
Mills, N. ChemDraw ultra 10.0. J. Am. Chem. Soc., 2006, 128(41), 13649-13650.
[http://dx.doi.org/10.1021/ja0697875]
[11]
Leach, A.R.; Gillet, V.J.; Lewis, R.A.; Taylor, R. Three-dimensional pharmacophore methods in drug discovery. J. Med. Chem., 2010, 53(2), 539-558.
[http://dx.doi.org/10.1021/jm900817u] [PMID: 19831387]
[12]
Shoichet, B.K. Virtual screening of chemical libraries. Nature, 2004, 432(7019), 862-865.
[http://dx.doi.org/10.1038/nature03197] [PMID: 15602552]
[13]
Mason, J.S.; Good, A.C.; Martin, E.J. 3-D pharmacophores in drug discovery. Curr. Pharm. Des., 2001, 7(7), 567-597.
[http://dx.doi.org/10.2174/1381612013397843] [PMID: 11375769]
[14]
Langer, T.; Krovat, E.M. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discov. Devel., 2003, 6(3), 370-376.
[PMID: 12833670]
[15]
Koes, D.R.; Camacho, C.J. Pharmer: efficient and exact pharmacophore search. J. Chem. Inf. Model., 2011, 51(6), 1307-1314.
[http://dx.doi.org/10.1021/ci200097m] [PMID: 21604800]
[16]
Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2005, 45(1), 160-169.
[http://dx.doi.org/10.1021/ci049885e] [PMID: 15667141]
[17]
Schuster, D.; Langer, T. The identification of ligand features essential for PXR activation by pharmacophore modeling. J. Chem. Inf. Model., 2005, 45(2), 431-439.
[http://dx.doi.org/10.1021/ci049722q] [PMID: 15807509]
[18]
Andersen, K.; Liljefors, T.; Gundertofte, K.; Perregaard, J.; Bøgesø, K.P. Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors. J. Med. Chem., 1994, 37(7), 950-962.
[http://dx.doi.org/10.1021/jm00033a013] [PMID: 8151622]
[19]
Mokrosz, M.J.; Strekowski, L.; Kozak, W.X.; Duszyńska, B.; Bojarski, A.J.; Kłodzinska, A.; Czarny, A.; Cegła, M.T.; Dereń-Wesoøek, A.; Chojnacka-Wójcik, E.; Dove, S.; Mokrosz, J.L. Structure-activity relationship studies of CNS agents, Part 25. 4,6-di(heteroaryl)-2-(N-methylpiperazino)pyrimidines as new, potent 5-HT2A receptor ligands: a verification of the topographic model. Arch. Pharm. (Weinheim), 1995, 328(9), 659-666.
[http://dx.doi.org/10.1002/ardp.19953280906] [PMID: 7487423]
[20]
Westkaemper, R.B.; Glennon, R.A. Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands. Curr. Top. Med. Chem., 2002, 2(6), 575-598.
[http://dx.doi.org/10.2174/1568026023393741] [PMID: 12052195]
[21]
Minitab® 17, http://www.minitab.com
[22]
Bagchi, M.C.; Mills, D.; Basak, S.C. Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. smegmatis using theoretical molecular descriptors. J. Mol. Model., 2007, 13(1), 111-120.
[http://dx.doi.org/10.1007/s00894-006-0133-z] [PMID: 16932890]
[23]
Nandi, S.; Bagchi, M.C. QSAR of aminopyrido[2,3-d]pyrimidin-7-yl derivatives: anticancer drug design by computed descriptors. J. Enzyme Inhib. Med. Chem., 2009, 24(4), 937-948.
[http://dx.doi.org/10.1080/14756360802519327] [PMID: 19555178]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy